Dykema Transaction Named a Finalist in D CEO Magazine’s 2022 M&A Dealmakers of the Year Awards

March, 2022 - Dallas, Texas

Dykema is proud to announce that XIFIN’s acquisition of OmniSYS, a deal led by Eric White, was recognized as a finalist for “Deal of the Year” ($250-$999M) in D CEO Magazine’s 2022 M&A Dealmakers of the Year Awards. The finalists will be featured in the May edition and celebrated at an in-person event on May 5, 2022, at On The Levee in Downtown Dallas.

In partnership with the Association for Corporate Growth, D CEO Magazine is recognizing the best, most notable, and most influential professionals leading the field. The top bankers, investment bankers, private equity leaders, lawyers, and advisors will be honored as the North Texas deals and dealmakers who stood out in 2021’s M&A Super Cycle.

In December 2021, XIFIN announced the strategic acquisition of OmniSYS, a leading provider of technology solutions for the retail pharmacy industry. The transaction expanded on XIFIN’s role as a top provider of solutions and services that improve the billing and claims process, provide healthcare leaders with significant business visibility, and support patient engagement. It further broadened and deepened the idea of software as a service in the healthcare arena, since XIFIN has already modernized the areas of radiology and imagery. Furthermore, doors have been opened for job creation and for greater services to be brought to North Texas.

The Dykema attorneys who assisted on the deal include the main deal team of Ryan Alexander, Oscar Garcia-Isita Munoz, Robert Fisher, Taylor Calvert, Antonio Cifuentes, and Ximena Lastra, as well as the following contributors, Jerry Aben, Tom Alleman, Amy Christen, Ryan Dadgari, Eric Fingerhut, Brian Forbes, Sean Griffin, Meg Hunter, Howard Iwrey, Eric Klein, Richard Lieberman, Cindy Motley, Kathy Reed, Dante Stella, and Elizabeth Voss.

About XIFIN, Inc.

XIFIN is a healthcare information technology company that leverages diagnostic information to improve the quality and economics of healthcare. The company's cloud-based technology facilitates connectivity and workflow automation for accessing and sharing clinical and financial diagnostic data, linking healthcare stakeholders in the delivery and reimbursement of care. The company provides cross-specialty industry analytics including its Lab Volume Index which provides a measurement of laboratory testing volumes across the U.S. Its synthesis of diagnostic data enables comparisons of hospital, genetics, pathology, routine lab, COVID-19, and antibody testing across key segments. To learn more, visit www.XIFIN.com.